SANOFI CONS HEALTHC IND L (SANOFICONR) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of SANOFI CONS HEALTHC IND L ₹4,061, price ₹3,787, upside +7.2%, quality 90 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SANOFI CONS HEALTHC IND L for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
25‑month range ₹3,787 – ₹5,610 · fair‑value band ₹2,582 – ₹5,000 · the ₹3,787 price screens below the ₹4,061 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow SANOFI CONS HEALTHC IND L in your weekly email
Every Wednesday you see whether SANOFI CONS HEALTHC IND L is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India.
Show more
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
Stock analysis
SANOFI CONS HEALTHC IND L (SANOFICONR) currently trades at ₹3,787, while our model-based Fair Value estimate is ₹4,061, so the stock looks roughly fairly valued today (gap 6.7%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹3,370 per share, and 1 of the 26 models we run sit above the ₹3,787 price.
Bear case: the Dividend Discount group reads lowest at ₹703.55, and 25 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹2,582 (bear) to ₹5,000 (bull), the price of ₹3,787 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 90/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
SANOFI CONS HEALTHC IND L reported revenue of ₹8.8B in FY2025 versus ₹5.4B in FY2023, a compound +27.0%/yr. Reported net income was ₹2.4B in FY2025, compounding +20.7%/yr from FY2023.
Key figures
Market cap ₹87.1B (≈ $904M) · P/E ratio 32.7 · P/S ratio 8.94 · EPS (TTM) ₹115.61 · Dividend yield 1.2% · Net margin 27.3% · Return on equity 88.0% · Return on assets (EBIT) 59.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 7%, SANOFICONR screens cheaper than that median.
Fair Value models
Bear ₹2,582Fair Value ₹4,061Bull ₹5,000
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹87.10 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +27.4% a year for the price.
Compare SANOFI CONS HEALTHC IND L with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score89 · Top 25%
Fair Value upside+7.2% · Above median
Profitability
Return on equity (TTM)73.1% · Top 25%
Return on assets38.0% · Top 25%
Net margin (TTM)27.6% · Top 25%
Operating margin (TTM)37.4% · Top 25%
Growth and dividend
Revenue growth32.8% · Top 25%
Dividend yield (TTM)1.2% · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SANOFI CONS HEALTHC IND L Fair Value". https://www.fairvalue-calculator.com/stock/SANOFICONR
Frequently asked questions
Is SANOFI CONS HEALTHC IND L (SANOFICONR) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹4,061 versus a price of ₹3,787, about +7% upside (fairly valued).
What is the fair value of SANOFICONR?
Our model-based fair value for SANOFI CONS HEALTHC IND L is ₹4,061 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹3,787.
What is the quality score of SANOFICONR?
SANOFI CONS HEALTHC IND L has a Quality Score of 90/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SANOFI CONS HEALTHC IND L (SANOFICONR)?
Our model-based price target is the fair value of ₹4,061 (as of Oct 2, 2026) from 26 valuation models. Cautious scenario ₹2,582, optimistic scenario ₹5,000. It is a calculation from audited fundamentals, not an analyst target.
What is the SANOFI CONS HEALTHC IND L stock forecast for 2026?
Our models put fair value at ₹4,061, about +7% upside versus a price of ₹3,787 (fairly valued). Cautious scenario ₹2,582, optimistic scenario ₹5,000. The calculation is refreshed regularly with new filings.
What is the revenue of SANOFI CONS HEALTHC IND L (SANOFICONR)?
SANOFI CONS HEALTHC IND L reported trailing-twelve-month revenue of about ₹9.5B (latest available figure, as of Oct 2, 2026).
Does SANOFI CONS HEALTHC IND L pay a dividend?
SANOFI CONS HEALTHC IND L currently shows a dividend yield of about 1.19% relative to its recent price (as of Oct 2, 2026).
What growth is priced into SANOFI CONS HEALTHC IND L (SANOFICONR)?
For today's price to be fair in a discounted-cash-flow model, SANOFI CONS HEALTHC IND L would have to grow free cash flow by +32.7 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +27.0 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of SANOFICONR use?
Our models discount SANOFI CONS HEALTHC IND L at 12.4 %: a base by market capitalisation (small), damped by beta 0.24, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SANOFI CONS HEALTHC IND L that is +32.7 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has SANOFI CONS HEALTHC IND L (SANOFICONR) delivered so far?
Over the past 2 years revenue at SANOFI CONS HEALTHC IND L grew +27.0 % a year. The price currently implies +32.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SANOFI CONS HEALTHC IND L (SANOFICONR) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into SANOFI CONS HEALTHC IND L (+32.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The free-cash-flow yield on the price is 2.07 %: that much free cash flow SANOFI CONS HEALTHC IND L produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SANOFI CONS HEALTHC IND L it is ₹4,061 per share (as of Oct 2, 2026), against a price of ₹3,787. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is SANOFI CONS HEALTHC IND L stock overvalued or undervalued in 2026?
As of Oct 2, 2026, SANOFICONR trades below its calculated fair value: price ₹3,787, fair value ₹4,061, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANOFICONR?
No. The price is what the market pays today (₹3,787); the fair value is what the company's own numbers justify (₹4,061). For SANOFI CONS HEALTHC IND L the two are ₹273.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is SANOFI CONS HEALTHC IND L worth?
The market values SANOFI CONS HEALTHC IND L at about ₹87.1B (market capitalisation, as of Oct 2, 2026). Per share that is ₹3,787; our models calculate a fair value of ₹4,061 per share.
What do the bullish and bearish scenarios say about SANOFICONR?
Our models span a range for SANOFI CONS HEALTHC IND L: cautious scenario ₹2,582, base ₹4,061, optimistic ₹5,000 per share (as of Oct 2, 2026, price ₹3,787). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SANOFICONR?
SANOFI CONS HEALTHC IND L trades at a price-to-earnings ratio of 32.7 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹4,061 is built from several models across several years. Other multiples: P/B 27.8, P/S 11.4, EV/EBITDA 30.7.
How solid is the balance sheet of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Balance-sheet figures for SANOFI CONS HEALTHC IND L (as of Oct 2, 2026): return on equity 73.1%. They feed the Quality Score of 90/100, which measures business quality independently of the share price.
How far is SANOFICONR from its 52-week high?
SANOFI CONS HEALTHC IND L trades at ₹3,787, about 24% below its 52-week high of ₹4,951 and at the low of ₹3,787 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4,061 is for.
Which stocks are comparable to SANOFI CONS HEALTHC IND L?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SANOFI CONS HEALTHC IND L stock attractive at the current price?
The data as of Oct 2, 2026: price ₹3,787, calculated fair value ₹4,061 (+7%), Quality Score 90/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SANOFICONR calculated?
We run SANOFI CONS HEALTHC IND L through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹4,061, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. SANOFI CONS HEALTHC IND L currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The closing price on Oct 1, 2026 was ₹3,787. Our model-based fair value is ₹4,061, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SANOFI CONS HEALTHC IND L right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹2,582 to ₹5,000) leaves room in how you read the outcome.
Key figures of SANOFI CONS HEALTHC IND L
How large is the market capitalisation of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The market capitalisation of SANOFI CONS HEALTHC IND L is ₹87.1B (≈ $904M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The price-to-sales ratio of SANOFI CONS HEALTHC IND L is 8.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SANOFI CONS HEALTHC IND L (SANOFICONR)?
Earnings per share at SANOFI CONS HEALTHC IND L are ₹115.61 (price ÷ EPS = P/E 32.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The dividend yield of SANOFI CONS HEALTHC IND L is 1.2% (payout 38.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The net margin of SANOFI CONS HEALTHC IND L is 27.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The return on equity (ROE) of SANOFI CONS HEALTHC IND L is 88.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SANOFI CONS HEALTHC IND L (SANOFICONR)?
On an EBIT basis the return on assets of SANOFI CONS HEALTHC IND L is 59.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SANOFI CONS HEALTHC IND L (SANOFICONR)?
The operating margin of SANOFI CONS HEALTHC IND L is 36.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SANOFI CONS HEALTHC IND L (SANOFICONR)?
Revenue at SANOFI CONS HEALTHC IND L is growing +6.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SANOFI CONS HEALTHC IND L (SANOFICONR)?
Earnings per share at SANOFI CONS HEALTHC IND L are growing +13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SANOFI CONS HEALTHC IND L (SANOFICONR) hold?
SANOFI CONS HEALTHC IND L holds more cash than debt, ₹3.5B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch SANOFI CONS HEALTHC IND L in the live analysis
One click puts SANOFI CONS HEALTHC IND L on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
